BioSpace News Archive

ARUP Laboratories today announced the formation of the new ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ (R&I Institute).

Bloom Burton & Co. (“Bloom Burton”) is pleased to announce Stephen Dilly, former Chief Executive Officer of Sierra Oncology, as the recipient of the 2023 Bloom Burton Award.

Foresee Pharmaceuticals, announced preclinical data in Nature Communications, demonstrating that activation of Aldehyde Dehydrogenase 2 with Foresee’s oral ALDH2 activator AD-9308, significantly ameliorates diet-induced obesity and fatty liver, and improves glucose homeostasis in both male Aldh2 wild-type and dominant-negative Glu504Lys knock-in mice with diet-induced obesity.

Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin.

Biomic Sciences is voluntarily recalling all lots of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray products to the consumer level.

Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA.

INVO Bioscience, Inc. announced that its special meeting of shareholders on September 29, 2023 was convened and then adjourned, without conducting any business, in order to provide shareholders additional time within which to vote on the proposals as described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on September 1, 2023.

Oragenics, Inc. and Lantern Bioworks announce a groundbreaking partnership, marked by the formalization of a materials transfer agreement.

NANOBIOTIX announced the oral presentation of the final readout on primary objectives from Study 102 Dose Expansion—the expansion part of a Phase 1 dose escalation and dose expansion study evaluating potential first-in-class radioenhancer NBTXR3 for elderly patients with locally advanced head and neck cancer—at the 65th Annual Meeting of the American Society for Radiation Oncology.

Cidara Therapeutics, Inc. announced that the Compensation Committee of its Board of Directors granted Nicole Davarpanah, M.D., J.D., a new employee, a non-qualified stock option award and restricted stock units for an aggregate of 330,000 shares of its common stock, pursuant to the Cidara Therapeutics, Inc.